What is the basis of drug treatment selection for hyperuricemia?

Updated: Aug 31, 2018
  • Author: James W Lohr, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Pharmacotherapy for hyperuricemia is based on whether patients are overproducers or undersecretors. Allopurinol continues to be the mainstay for the treatment of patients who are overproducers, but febuxostat has become an established alternative to allopurinol. Febuxostat is a nonpurine selective xanthine oxidase inhibitor that does not require dose reduction in patients with renal impairment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!